We have shown recently that by acting on the thyroid-stimulating hormone (TSH) receptor (TSHR), TSH negatively regulates osteoclast differentiation. Both heterozygotic and homozygotic TSHR null mice are osteopenic with evidence of enhanced osteoclast differentiation. Here, we report that the accompanying elevation of TNF␣, an osteoclastogenic cytokine, causes the increased osteoclast differentiation. This enhancement in TSHR ؊/؊ and TSHR ؉/؊ mice is abrogated in compound TSHR ؊͞؊ ͞TNF␣ ؊/؊ and TSHR ؉/؊ ͞ TNF␣ ؉/؊ mice, respectively. In parallel studies, we find that TSH directly inhibits TNF␣ production, reduces the number of TNF␣-producing osteoclast precursors, and attenuates the induction of bone remodeling ͉ osteoclast ͉ macrophage ͉ cytokine A nterior pituitary hormones have long been thought just to stimulate the secretion of master hormones from target endocrine glands, except for our recent demonstration of direct effects of thyroid-stimulating hormone (TSH) and folliclestimulating hormone on the skeleton (1). Thus, until recently, TSH was considered solely to regulate thyroid follicular cell differentiation and thyroid hormone secretion by binding to a seven transmembrane, glycosylated G protein-coupled receptor, the TSH receptor (TSHR). Previous studies had identified TSHRs in other tissues and cells, including the pituitary, thymus, testes, kidney, brain, lymphocytes, adipocytes, and fibroblasts (2, 3), but their functional significance has remained uncertain.
A nterior pituitary hormones have long been thought just to stimulate the secretion of master hormones from target endocrine glands, except for our recent demonstration of direct effects of thyroid-stimulating hormone (TSH) and folliclestimulating hormone on the skeleton (1) . Thus, until recently, TSH was considered solely to regulate thyroid follicular cell differentiation and thyroid hormone secretion by binding to a seven transmembrane, glycosylated G protein-coupled receptor, the TSH receptor (TSHR). Previous studies had identified TSHRs in other tissues and cells, including the pituitary, thymus, testes, kidney, brain, lymphocytes, adipocytes, and fibroblasts (2, 3) , but their functional significance has remained uncertain.
Gene ablation studies in mice revealed that TSHR haploinsufficiency did not affect thyroid gland development or function, whereas the total absence of the TSHR expectedly disrupted thyroid follicular structure (4) . However, bone mass was reduced not only in homozygote mice but also in the haploinsufficient heterozygotes (5) . That TSHR haploinsufficiency, in the absence of a thyroid defect, resulted in osteoporosis established a primary role for the TSHR in bone metabolism. Furthermore, supplementation of TSHR Ϫ/Ϫ mice with thyroid extract to render them euthyroid corrected all hypothyroid abnormalities, including runting, but not reductions in bone mass (5) or sodium-iodide symporter expression (4) . The latter observation confirmed that the osteoporosis arose from TSHR deficiency rather than altered thyroid hormone levels. Consistent with this notion, the genetic ablation of the ␣1͞␤ thyroid hormone receptor has been shown not to result in a bone remodeling defect (6) .
We found that the osteoporosis in TSHR knockout mice was the result of an enhancement in osteoclast differentiation. Consistent with the low bone mass, ex vivo cultures of bone marrow cell precursors from both heterozygote and homozygote mice showed increased osteoclast formation and the enhanced expression of an osteoclast marker tartrate-resistant acid phosphatase (TRAP) (5) . This enhanced osteoclast formation was not associated with increased receptor activator of NF-B ligand (RANKL) production but instead with a several-fold increase in the synthesis and release of TNF␣, another osteoclastogenic cytokine (5) . A blocking antibody to TNF␣ abrogated this increased osteoclastogenesis, suggesting that the osteoporosis in the TSHR Ϫ/Ϫ mice was TNF␣-mediated. Several studies have implicated elevated TNF␣ in the pathogenesis of various forms of osteoporosis (7) . For example, TNF␣ is overexpressed in T lymphocytes in hypogonadal animal models and humans (7, 8) , and T cell-deficient mice are resistant to hypogonadal osteoporosis. Likewise, the systemic osteoporosis and juxtaarticular osteolysis that accompany rheumatoid arthritis are thought to be TNF␣-mediated (9, 10) . There is recent evidence indicating that the systemic and local bone loss can be abrogated by a TNF␣ antibody (11) . The osteoporosis seen in hyperthyroidism is also associated with increased levels of various inflammatory cytokines, including TNF␣, IL-1, and IL-6 (12).
To examine whether TNF␣ plays a critical role in mediating the skeletal effects of TSH, we (i) investigated whether the enhanced osteoclast formation can be rescued by abrogating TNF␣ in TSHR Ϫ/Ϫ and TSHR ϩ/Ϫ mice and (ii) determined the mechanism by which TSH regulates TNF␣ production. For the former experiments, we measured osteoclast formation and TRAP expression in TSHR Ϫ/Ϫ ͞TNF␣ Ϫ/Ϫ and TSHR Ϫ/Ϫ ͞TNF␣ ϩ/Ϫ mice, as well as in TSHR haploinsufficient mice that had one TNF␣ allele deleted. The increased osteoclastogenesis in both TSHR homozygote and heterozygote mice was rescued with graded reductions in the dosage of the TNF␣ gene. For the latter experiments, we constructed a constitutively active TSHR (caTSHR) with a single point mutation, Asp to Ala at 633 (13) . This transmembrane ligandindependent, gain-of-function mutation has been identified in patients with autonomous thyroid adenomas and nonautoimmune hereditary hyperthyroidism. Overexpression of this mutant construct in primary murine macrophages and RAW-C3 cells demonstrated that TSH͞TSHR regulates transcription of the TNF␣ gene and osteoclast formation.
Results

TNF␣ Gene Deletion Rescues the Enhanced Osteoclastogenesis in the
TSHR-Null Mouse. We have shown previously that TNF␣ mRNA and protein levels are increased in the bone marrow of TSHR Ϫ/Ϫ mice (5) . We have further demonstrated that osteoclast formation is enhanced in TSHR Ϫ/Ϫ and TSHR ϩ/Ϫ mice and that an antibody to TNF␣ abrogates this increase (5) . To examine a cause-effect relationship, i.e., whether the increased TNF␣ expression causes the enhanced osteoclastogenesis, we crossed TSHR ϩ/Ϫ mice with TNF ϩ/Ϫ mice and examined osteoclast formation and TRAP expression in bone marrow cultures from the resulting genotypes. We confirmed an increase in osteoclast formation and TRAP expression in TSHR Ϫ/Ϫ ͞TNF ϩ/ϩ and TSHR ϩ/Ϫ ͞TNF ϩ/ϩ mice compared with wild-type controls. These increases in osteoclastogenesis and TRAP mRNA expression were abrogated in TSHR Ϫ/Ϫ ͞TNF␣ Ϫ/Ϫ and TSHR ϩ/Ϫ ͞TNF␣ ϩ/Ϫ mice, respectively ( Fig. 1 A and B and Fig. 8 , which is published as supporting information on the PNAS web site). Consistent with a dose-dependent effect of TNF␣, deletion of the TNF␣ gene from one allele only partly attenuated the increased osteoclastogenesis and TRAP expression in TSHR Ϫ/Ϫ mice. Overall, therefore, our finding that the deletion of the TNF gene fully rescues the increased osteoclastogenesis in TSHR null mice establishes that TNF mediates the skeletal effect of TSH.
In addition to the elevated TNF expression, we found that other proinf lammatory cytokines were also elevated in TSHR Ϫ/Ϫ bone marrow cell cultures (Fig. 1C) . However, TNF, but not IL-1 or IL-6, expression was significantly enhanced in heterozygotic TSHR ϩ/Ϫ mice, suggesting that the effect of TNF␣ in mediating the skeletal effects of TSHR deletion was dominant. Nonetheless, we cannot rule out the role of other cytokines in the increased osteoclast formation caused by TSHR deletion, because all of the other cytokines of interest, including IL-6 and IL-1, are known to affect osteoclastogenesis (14) .
TSH Signals Directly Inhibit TNF␣ Gene Expression and Osteoclastogenesis. Gain-of-function studies were performed to determine whether the addition of TSH directly inhibited TNF␣ expression. We first tested the induction of TNF␣ expression in CD11b ϩ bone marrow macrophages and RAW-C3 cells by IL-1 or TNF␣ alone, or a combination of IL-1 and TNF␣ (IL-1͞TNF) (Fig. 9 , which is published as supporting information on the PNAS web site). A robust stimulation of TNF␣ expression was observed in response to IL-1 and TNF␣ together compared with each cytokine alone. Thus, we used IL-1 and TNF␣ in combination in the next experiments to examine TSH effect.
We found that IL-1͞TNF␣-induced TNF␣ mRNA expression was significantly attenuated in the presence of TSH both in RAW-C3 cells and CD11b ϩ bone marrow cells ( Fig. 2 A and B) . Consistent with the decreased TNF␣ mRNA expression, TSH also significantly reduced the level of TNF␣ secreted in response to murine recombinant IL-1͞human recombinant TNF␣, as measured by a murine-specific TNF␣ ELISA ( Fig. 2 C and D) . Similar to IL-1͞TNF␣, the addition of RANKL elicited a several-fold increase in TNF␣ mRNA expression (data not shown). Taken together, the findings indicate that TSH directly inhibits TNF␣ expression in osteoclast precursors.
We have shown previously that the TSHR is expressed in bone marrow macrophages and RAW-C3 cells, and that its expression becomes elevated during osteoclast differentiation (5) . Thus, we studied the effect of overexpressing the TSHR by stably transfecting RAW-C3 cells with the wild-type TSHR (TSHR-C3) or the constitutively active TSHR (caTSHR-C3) tagged with EGFP. TSHR mRNA expression measured by real-time PCR showed a 2.5-and 1.5-fold increase in TSHR-C3 and caTSHR-C3 cells, respectively. Consistent with this result, flow cytometery using MS-1, a hamster TSHR monoclonal antibody (15) , revealed that 45% cells in empty-C3 and 73% and 55% in TSHR-and caTSHR-C3, respectively, were positive for the TSHR protein (nonspecific binding using control IgG at 27.0%, 28.5%, and 26.2%, respectively). Compared with previous CHO cell experiments (15) , TSHR overexpression in RAW-C3 cells was relatively low. As intensely fluorescent cells became large and flat and stopped proliferation, cells expressing high levels of TSHR or caTSHR were likely eliminated during the selection procedure. This analysis was performed on pooled cells to minimize clone-to-clone variation.
Empty-C3, TSHR-C3, and caTSHR-C3 cells showed no difference in basal TNF␣ expression (Fig. 3A) . However, the overexpression of the TSHR or caTSHR significantly attenuated the increased TNF␣ mRNA expression triggered by IL-1͞TNF␣ or RANKL. We then performed promoter-reporter assays to determine whether the inhibitory effect of TSH on TNF␣ was because of a direct effect on gene expression. A 197-bp TNF␣ promoter-luciferase construct was transfected into empty-C3, TSHR-C3, and caTSHR-C3 cells, and the protein kinase C agonist PMA (phorbol 12-myristate 13-acetate) was used to activate TNF␣ gene transcription. Although basal luciferase activity did not differ between the three groups, the PMAinduced stimulation of TNF␣ gene transcription was substantially reduced in cells transfected with either TSHR or caTSHR (Fig. 3B) . Recombinant TSH attenuated the response to PMA in empty-C3 cells, but not in TSHR-or caTSHR-infected cells (Fig. 3B ). This result indicates TSHR overexpression could regulate TNF␣ expression in osteoclast progenitors. It remains unclear how TSHR, in the absence of ligand, reduces TNF␣ expression. It is possible that high, nonphysiological levels of TSHR expression could trigger specific signaling in those cells.
We next examined the effects of TSH on the TRAP-positive osteoclast formation induced by RANKL. The osteoclast formation was inhibited strongly in caTSHR-C3 cells, even in the absence of TSH (Fig. 4A) . Additionally, TSH caused a further concentrationdependent decrease in osteoclastogenesis from empty-C3 or TSHR-C3 cells, and this decrement was expectedly greater in TSHR-C3 cells (Fig. 4A) . Fig. 4B likewise shows that bone marrow cells infected transiently with a retrovirus containing caTSHR or TSHR displayed a significant attenuation of osteoclastogenesis compared with vector-infected cells. Finally, TSH did not reduce osteoclastogenesis in cells infected with caTSHR. Note that TSHR overexpression inhibits TNF␣ but not osteoclastogenesis in the absence of TSH, whereas caTSHR inhibits both (cf. Figs. 3A and 4A ). The different action in TSHR and caTSHR cells may arise from the distinct sensitivities of gene expression and osteoclast formation. Thus, even at relatively high levels of TSHR, the expression of a single gene, such as TNF␣, may be inhibited, whereas osteoclast formation may not, because the latter depends on a full program of gene expression. In contrast, more profound signaling by caTSHR may inhibit the other TSHsensitive genes causing osteoclast formation to decline.
TSH Inhibits Osteoclast Precursor Proliferation and Downstream Sig-
naling. As TNF␣ is produced mainly in hematopoetic precursors and because total bone marrow TNF␣ levels depend on the relative abundance of TNF␣-producing cells, we examined whether there were significant differences in the populations of CD11b
ϩ , CD3 ϩ (T lymphocytes), and B220 ϩ B cells in the TSHR genotypes. We found that CD11b ϩ and CD45 ϩ precursor populations were significantly increased in both TSHR Ϫ/Ϫ and TSHR ϩ/Ϫ mice, whereas the B220 ϩ cell population was reduced (Fig. 5A) . This phenomenon is similar to that seen in oc͞oc mice (16) . No significant increases were noted in the relatively minor populations of CD4 ϩ , CD8 ϩ , CD3 ϩ , and CD90 ϩ T cells (Fig. 5A ). To confirm the increased osteoclast precursor populations, we quantitated M-CSF-dependent macrophage numbers in colony forming units-macrophage (CFU-M) assays. There was a significant increase in CFU-M formation both in TSHR ϩ/Ϫ and TSHR Ϫ/Ϫ mice compared with wild-type littermates (Fig. 5B) . Furthermore, TSH significantly reduced CFU-M formation in a concentration-dependent manner (Fig. 5C) . Importantly, BrdU assays demonstrated a clear effect of TSH in reducing the proliferation of CD11b ϩ osteoclast precursors (Fig. 5D ). We next attempted to (i) determine which specific bone marrow cell populations expressed the TSHR and (ii) study the mechanism through which the expression of TSHRs is regulated. Flow cytometry was used to examine TSHR expression on isolated CD11b ϩ , B220 ϩ , CD3 ϩ , CD106 ϩ (stromal cells), and primary calvarial osteoblasts (POB). Fig. 6A shows that B220 ϩ and CD3 ϩ cells exhibited low TSHR expression compared with CD11b ϩ or CD106 ϩ cells or osteoblasts. Furthermore, TSHR mRNA and protein expression in CD11b ϩ cells was enhanced by not only RANKL but also by IL-1͞TNF␣ (Fig. 6 B and C) . In contrast, TSHR expression in B220 ϩ and CD3 ϩ cells was insensitive to IL-7 and Con A, respectively (data not shown). Together, the results indicate that TSHR is expressed in TNF␣-expressing osteoclast and osteoblast progenitors but not in B or T lymphocytes. Furthermore, it is clear that TNF production and TSHR expression are both regulated by IL-1, TNF, and RANKL during osteoclast activation and formation.
We next tested the hypothesis that TSH interferes with downstream signals evoked by RANKL and IL-1͞TNF. AP-1 and NF-B binding to DNA were thus studied in empty-C3, TSHR-C3, and caTSHR-C3 cells using EMSA. In empty-C3 cells, at both 40 and 60 min post-RANKL, and 60 min post-IL-1͞TNF exposure, there was a significant increase in binding of AP-1 (Fig. 7) . However, there was an unexpected increase in basal AP-1-and NF-B-DNA binding in TSHR-C3 and caTSHR-C3 cells without treatment and RANKL or IL-1͞TNF␣ failed to further increase in the DNA binding in those cells (Fig. 7) . These data suggest that the TSHR signaling interferes with downstream AP-1-and NF-B-DNA binding to account for the reduced TNF␣ expression and osteoclastogenesis. We are aware that in other TSH-responsive cells, such as thyroid cells or CHO cells overexpressing TSHR, there is a stimulation of cAMP (15, 17) . However, we did not find the same phenomenon in RAW-C3 cells even after transfected with TSHR or caTSHR ( Fig. 10 and Supporting Text, which are published as supporting information on the PNAS web site).
Discussion
Proinflammatory cytokines such as TNF␣, IL-1, and IL-6 stimulate osteoclast formation, activation, and survival (14) . These cytokines are increased in various osteoporoses and are thought to contribute to the bone loss. Most notably, enhanced TNF␣ production from T cells has been implicated in the genesis of postmenopausal osteoporosis (7, 8) . Additionally, various clinical features of hyperthyroidism, including the high turnover osteoporosis, have been attributed to elevated levels of cytokines such as TNF and their soluble receptors (12) .
We showed previously that an elevated TNF␣ production accompanies the osteopenia and increased osteoclastogenesis of TSHR deficiency (5) . Preliminary studies had also indicated that this increased osteoclast formation was abrogated with an anti-TNF␣ blocking antibody. Here, we provide unequivocal genetic evidence that TNF␣ mediates the increased osteoclastogenesis resulting from TSHR deficiency. The ex vivo phenotype in TSHR Ϫ/Ϫ and TSHR ϩ/Ϫ mice was abrogated in compound TSHR Ϫ/Ϫ TNF Ϫ/Ϫ and TSHR ϩ/Ϫ TNF ϩ/Ϫ mutants, respectively. Furthermore, although all three cytokines, TNF␣, IL-1, and IL-6, were elevated in TSHR Ϫ/Ϫ cultures, only TNF␣ was elevated in the cultures from heterozygote mice, indicating a dominant effect of TNF␣. Together, the data strongly support our conclusion that enhanced TNF␣ expression mediates the increased osteoclastogenesis and bone loss of TSHR deficiency.
We next studied the cellular mechanism through which TSH regulates TNF␣ expression and osteoclast formation. That TSH acts solely through CD11b ϩ osteoclast progenitors was attested by the following observations. First, TNF␣-producing CD11b ϩ positive cells were increased in bone marrow isolated freshly from TSHR ϩ/Ϫ and TSHR Ϫ/Ϫ mice. Second, M-CSF-dependent macrophage colony formation was increased in TSHR ϩ/Ϫ and TSHR Ϫ/Ϫ mice, and was decreased with recombinant TSH. Finally, TSH attenuated cytokine-induced TNF␣ mRNA and protein expression only in CD11b ϩ cells via a transcriptional effect involving AP-1 and NFB activation.
Similarly to TSHR-null mice, selective enhancements in TNF␣-producing CD11b ϩ cells have also been reported in oc͞oc and TNF␣ transgenic mice, as well as with TNF␣ administration (16, 18, 19) . As with TSHR Ϫ/Ϫ mice, enhanced CD11b ϩ cells in oc͞oc mice are accompanied by reduced B220 ϩ cells and enhanced osteoclastogenesis, albeit with dysfunctional osteoclasts. It is thus possible that TNF␣ stimulates the common progenitor toward CD11b ϩ formation, as suggested in ref. 20 .
In contrast to TSHR deficiency, estrogen deficiency is characterized by an increase in the population of TNF␣-producing T lymphocytes (7). This enhancement is considered primary and of pathophysiological significance in mediating hypogonadal bone loss. During estrogen deficiency, T cell-derived TNF␣ is enhanced through the actions of IL-7, IFN-␥, and TGF␤ (7). The apparent difference between the cellular effects of estrogen and TSHR deficiency may be the consequence of the distinct patterns of estrogen and TSH receptor localization. Estrogen receptors are present on T cells, B cells, and, to some extent, macrophages (21) , whereas only CD11b ϩ macrophages in bone marrow express TSHRs.
Besides inhibiting TNF␣ expression in CD11b ϩ cells, TSH paradoxically increases TNF␣ expression in certain cell types including CD11b Ϫ bone marrow cells (22) , CD106 ϩ stromal cells, and primary calvarial osteoblasts (data not shown). In addition, TNF␣ attenuates osteoblast differentiation similarly to TSH (23) . We therefore speculate that the TSH-induced attenuation in osteoblast differentiation that we have noted earlier is also mediated via enhanced TNF␣ expression.
To explore the mechanism of the TSH effect on osteoclast inhibition, we measured NF-B-and AP-1-DNA binding activity and cAMP levels in RAW-C3 cells. We found that RANKL and IL-1͞TNF␣ failed to stimulate NF-B-and AP-1-DNA binding in cells overexpressing TSHR or caTSHR. This result suggests that the TSHR interferes with downstream AP-1 and NF-B signaling. The finding also supports our view that high, nonphysiologic levels of recombinant TSHR expression, in the absence of ligand, mimic the caTSHR in interfering with IL-1͞ TNF␣ and RANKL signaling and TNF␣ mRNA expression. The precise molecular details underlying this apparently ligand-less signaling by the wild-type receptor remains to be determined.
Another interesting observation was that TSH did not increase cAMP levels in RAW-C3 cells, although forskolin increased some levels of cAMP in those cells (Fig. 10) . In contrast, thyroid cells or CHO cells overexpressing the TSHR do respond to both TSH and forskolin with a marked stimulation of cAMP. The reason for this distinct action is unclear but may be somewhat explained by the differential, cell-specific coupling of the TSHR to a distinct G protein. Similar findings have been reported by us whereby the osteoclast follicle-stimulating hormone receptor couples to a G i2␣ , instead of a G s␣ , as reported in ovarian cells (24) . Alternatively, TSH may transduce nontraditional, noncAMP-dependent signals, as observed in preadipocytes and thyrocytes (25, 26) that include Ca 2ϩ transients, MAP kinases, p70 S6K, and protein kinase B͞Akt.
Finally, the question remains whether the skeletal effects of TSH mediated through TNF␣ are applicable to the osteoporosis and high fracture rates seen in hyperthyroidism. Indeed, there is a strong correlation between reduced TSH levels and fracture risk at both vertebral and nonvertebral sites (27) . Furthermore, this high remodeling bone loss is reminiscent of cytokineinduced osteoporosis, and there is growing evidence that thyrotoxic states in both humans and animals are associated with elevated IL-1␤, IL-6, and TNF␣, as well as their soluble receptors (28) (29) (30) . There is also evidence that TNF␣ polymorphisms are associated with Graves' disease (31) . Thus, the osteoporosis in human hyperthyroidism may also be TNF-driven, but this hypothesis needs clinical testing. mice were generated and maintained in-house by using standard protocols approved by Institutional Animal Care and Use Committee at Mount Sinai School of Medicine. TNF␣-null animals were obtained from The Jackson Laboratory (Bar Harbor, ME). Compound TSHR͞TNF␣ mutant mice were generated by crossing TSHR ϩ/Ϫ and TNF␣ ϩ/Ϫ animals.
Materials and Methods
Osteoclast Formation. TSHR and caTSHR cDNA plasmids were provided by G. Vassert (Universite Libre de Bruxelles, Bruxelles, Belgium) (13, 32) . The plasmids were subcloned into the expression vector with EGFP (CLONTECH, Mountain View, CA) and transfected into RAW-C3 cells by using Mirus-Neural (Mirus, Madison, WI) to establish stable transformants through G418 (geneticin) selection. Pooled cells were used for TNF␣ expression, NF-B-and AP-1 binding, and osteoclast formation experiments to minimize clone-clone variation. In the separate experiments, TSHR-EGFP or caTSHR-EGFP DNA fragments were also subcloned into a retroviral vector (pLXSN; CLONTECH) and transfected into a packaging cell line Plat-E (provided by I. Kitamura, Tokyo Medical Institute, Tokyo University, Tokyo, Japan) (33) by using Fugene 6 (Roche Applied Science, Indianapolis, IN). The supernatants were concentrated and used for transient infection into bone marrow macrophages in the presence of 4 g͞ml polybrene to examine osteoclast formation. For osteoclastogenesis assays, RAW-C3 cells with an empty vector (Empty-C3) or stable transformants overexpressing TSHR or caTSHR (TSHR-C3 or caTSHR-C3) were cultured with RANKL (100 ng͞ml) for 6 days. Bone marrow macrophages prepared by Ficoll-Plus (Amersham Pharmacia, Piscataway, NJ) were precultured with M-CSF (30 ng͞ml) and then infected with the respective virus and cultured with RANKL (60 ng͞ml) and M-CSF (30 ng͞ml) for 6 days (5). The osteoclasts formed either in RAW-C3 or bone marrow cell cultures were stained for TRAP.
Flow Cytometry. Cells in bone marrow were examined by flow cytometry using PE (phycoerythrin)-labeled CD11b, CD3, B220, CD90, CD45, CD4, and CD8 antibodies (PharMingen, San Diego, CA). TSHR expression was also detected by using RSR-1 (kindly provided by Bernard R. Smith; RSR Ltd., Cardiff, U.K.) (34) or MS-1 (15) antibodies. To avoid the binding of antibodies to Fc receptor, cells were preincubated with guinea pig serum and then incubated with TSHR antibodies or nonimmune IgG (isotype control). CD11b ϩ , B220
ϩ , or CD106 ϩ cells were isolated from fresh bone marrow, and CD3 ϩ cells were obtained from spleen cells by using magnetic beads (PharMingen).
ELISA and Luciferase Assays. TNF␣ production from RAW-C3 cells or bone marrow macrophages was measured by an ELISA kit (PharMingen), per manufacturer's protocol. For ELISA, murine IL-1␣ and human TNF␣ were added in RAW-C3 cells or CD11b ϩ macrophages for 24 h, and the supernatant was collected to measure murine TNF␣ levels. The antimurine TNF␣ antibody did not cross-react with recombinant human TNF␣.
For promoter assays, the murine TNF␣ promoter was PCRamplified, and its sequence was confirmed by matching to the known sequence provided by the National Center for Biotechnology Information. The cDNA obtained was then cloned into pGL3 basic luciferase plasmid (Promega, Madison, WI), and the resulting construct was transfected into RAW-C3 cells by using Mirus-Neural. Luciferase activity was measured by using a dual luciferase reporter assay system (Promega) with Renilla luciferase (Promega) to normalize transfection efficiency. PMA (Sigma-Aldrich), a potent inducer of TNF␣ promoter activity (35) , was used to stimulate TNF␣ transcription.
Gene Expression and M-CSF-Dependent Cell Proliferation. TNF␣, IL-1␣, IL-1␤, IL-6, TRAP, and TSHR mRNA expression were quantified by real-time PCR by using specific primer sets and iTaq SYBR green Supermix with a ROX kit (Bio-Rad, Hercules, CA). For cell proliferation studies, fresh bone marrow cells from TSHR ϩ/ϩ , TSHR ϩ/Ϫ , and TSHR Ϫ/Ϫ mice were cultured in the presence of 30 ng͞ml M-CSF in MethoCult (Stemcell Technologies, Vancouver, BC, Canada) for 7 days, and colonies containing Ͼ50 cells were counted. Proliferating CD11b ϩ macrophages were identified by the Cell Proliferation BrdU kit (Roche) at OD 450 .
EMSA. Nuclear fractions of nonstimulated and stimulated RAW-C3 cells were prepared as reported in ref. 5 . The nuclear fractions obtained were incubated with biotin-labeled consensus oligonucleotides prepared by using a biotin 3Ј-end DNA labeling kit (Pierce, Rockford, IL). The resulting oligonucleotide-transcription factor complexes were applied on a 6% acrylamid gel containing 0.5ϫ TBE and 2.5% glycerol. Consensus DNA sequences used for AP-1 and NF-B binding were CGCTTGATGAGTCAGGCCGGAA and AGTTGAGGGGACTTTCCCAGGC, respectively. Italicized nucleotide sequences are essential for DNA-protein binding.
Statistical Analyses. Statistically significant differences were analyzed by using one-way ANOVA test (P Ͻ 0.05), and data were presented as the mean Ϯ SEM. 
